Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

KRAS G12

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

KRAS amplification (7)

KRAS deletion (1)

KRAS amplification (7)

KRAS deletion (1)

›

KRAS G12	Colorectal Cancer	KRAS G12	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS G12	Colorectal Cancer	KRAS G12	Colorectal Cancer	trifluridine/tipiracil Resistant: B - Late Trials trifluridine / tipiracil Resistant : B	trifluridine/tipiracil Resistant: B - Late Trials trifluridine / tipiracil Resistant : B
KRAS G12	Ovarian Cancer	KRAS G12	Ovarian Cancer	cetuximab Resistant: C1 - Off-label cetuximab Resistant : C1	cetuximab Resistant: C1 - Off-label cetuximab Resistant : C1
KRAS G12	Non Small Cell Lung Cancer	KRAS G12	Non Small Cell Lung Cancer	RMC-6236 Sensitive: C2 – Inclusion Criteria RMC-6236 Sensitive : C2	RMC-6236 Sensitive: C2 – Inclusion Criteria RMC-6236 Sensitive : C2
KRAS G12	Colorectal Cancer	KRAS G12	Colorectal Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
KRAS G12	Colorectal Cancer	KRAS G12	Colorectal Cancer	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3
KRAS G12	Pancreatic Ductal Adenocarcinoma	KRAS G12	Pancreatic Ductal Adenocarcinoma	RMC-6236 Sensitive: C3 – Early Trials RMC-6236 Sensitive : C3	RMC-6236 Sensitive: C3 – Early Trials RMC-6236 Sensitive : C3
KRAS G12	Colorectal Cancer	KRAS G12	Colorectal Cancer	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
KRAS G12	Colorectal Cancer	KRAS G12	Colorectal Cancer	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D
KRAS G12	Colorectal Cancer	KRAS G12	Colorectal Cancer	selumetinib Sensitive: D – Preclinical selumetinib Sensitive : D	selumetinib Sensitive: D – Preclinical selumetinib Sensitive : D